Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis

BACKGROUND: Subcutaneous peginterferon beta-1a every 2 weeks significantly affects clinical outcomes in patients with relapsing–remitting multiple sclerosis (RRMS). OBJECTIVES: To explore relationships between relapses and worsening of disability in patients with RRMS, and assess the treatment effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Thomas F, Kieseier, Bernd C, Newsome, Scott D, Arnold, Douglas L, You, Xiaojun, Hung, Serena, Sperling, Bjoern
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433498/
https://www.ncbi.nlm.nih.gov/pubmed/28607743
http://dx.doi.org/10.1177/2055217316676644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433498/
https://www.ncbi.nlm.nih.gov/pubmed/28607743
http://dx.doi.org/10.1177/2055217316676644

Ejemplares similares